Please assess the completion status of the following clinical trial:

Trial Title: A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Multiple myeloma with relapsing or progressive disease at study entry~2. Measurable disease, as defined by 1 or more of the following (assessed within 21 days prior to enrollment):~   1. Serum M-protein ≥ 0.5 g/dL, or~  2. Urine M-protein ≥ 200 mg/24 hours, or~  3. Only in patients who do not meet a or b, then use serum free light chain (SFLC) \> 100 mg/L (involved light chain) and an abnormal kappa/lambda ratio~3. Prior treatment with 1 to 3 prior regimens for multiple myeloma for Phase 1 and Phase 2 (induction therapy followed by stem cell transplant and consolidation/maintenance therapy will be considered as 1 line of therapy~4. Age ≥ 18 years~5. Life expectancy ≥ 6 months~6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~7. Adequate hepatic function within 21 days prior to enrollment, with bilirubin \< 1.5 × the upper limit of normal (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 3 × ULN~8. Left ventricular ejection fraction (LVEF) ≥ 40%. 2-D transthoracic echocardiogram (ECHO) is the preferred method of evaluation. Multigated acquisition scan (MUGA) is acceptable if ECHO is not available~9. Absolute neutrophil count (ANC) ≥ 1000/mm³ within 21 days prior to enrollment. Screening ANC is to be independent of growth factor support for ≥ 1 week~10. Hemoglobin ≥ 8.0 g/dL within 21 days prior to enrollment. Use of erythropoietic stimulating factors and red blood cell (RBC) transfusions per institutional guidelines is allowed; however, most recent RBC transfusion must have been at least 7 days prior to obtaining screening hemoglobin~11. Platelet count ≥ 50,000/mm³ (≥ 30,000/mm³ if myeloma involvement in the bone marrow is \> 50%) within 21 days prior to enrollment. Patients must not have received platelet transfusions for at least 7 days prior to obtaining the screening platelet count~12. Calculated or measured creatinine clearance (CrCl) of ≥ 30 mL/min within 21 days prior to enrollment. Calculation based on standard formula, such as the Cockcroft and Gault: \[(140 - Age) x Mass (kg) / (72 x Creatinine mg/dL)\]; multiply result by 0.85 if female~13. Written informed consent in accordance with federal, local, and institutional guidelines~14. Female patients of childbearing potential (FCBP) must have a negative serum pregnancy test within 21 days prior to enrollment and agree to use an effective method of contraception during and for 3 months following last dose of drug (more frequent pregnancy tests may be conducted if required per local regulations). Postmenopausal females (\> 45 years old and without menses for \> 1 year) and surgically sterilized females are exempt from a pregnancy test~15. Male patients must agree to use an effective barrier method of contraception during study and for 3 months following the last dose if sexually active with an FCBP~Exclusion Criteria:~1. Multiple myeloma of Immunoglobulin M (IgM) subtype~2. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)~3. Plasma cell leukemia (\> 2.0 × 10\^9/L circulating plasma cells by standard differential)~4. Waldenström's macroglobulinemia~5. Amyloidosis~6. Glucocorticoid therapy (prednisone \> 30 mg/day or equivalent) within 7 days prior to enrollment~7. Cytotoxic chemotherapy with approved or investigational anticancer therapeutics within 28 days prior to enrollment~8. Treatment with bortezomib (Velcade®), thalidomide (Thalomid®) or lenalidomide (Revlimid®) within 21 days prior to enrollment~9. Focal radiation therapy within 7 days prior to enrollment. Radiation therapy to an extended field involving a significant volume of bone marrow within 21 days prior to enrollment (ie, prior radiation must have been to \< 30% of the bone marrow)~10. Immunotherapy within 21 days prior to enrollment~11. Major surgery within 21 days prior to enrollment~12. Active congestive heart failure (New York Heart Association \[NYHA\] Classes III to IV), symptomatic ischemia, or conduction abnormalities uncontrolled by conventional intervention. Myocardial infarction within 6 months prior to enrollment~13. Acute active infection requiring systemic antibiotics, antiviral (except antiviral therapy directed at hepatitis B virus \[HBV\]), or antifungal agents within 14 days prior to enrollment~14. Known human immunodeficiency virus (HIV) seropositivity~15. Known hepatitis B or C virus infection (except for patients with HBV who are receiving and responding to HBV antiviral therapy: these patients are allowed)~16. Patients with known cirrhosis~17. Second malignancy within the past 3 years, except:~    1. Adequately treated basal cell or squamous cell skin cancer~   2. Carcinoma in situ of the cervix~   3. Prostate cancer \< Gleason score 6 with stable prostate-specific antigen (PSA) over 12 months~   4. Breast carcinoma in situ with full surgical resection~   5. Treated medullary or papillary thyroid cancer~18. Patients with myelodysplastic syndrome~19. Significant neuropathy (Grades 3 to 4) within 14 days prior to enrollment~20. Female patients who are pregnant or lactating~21. Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib)~22. Prior carfilzomib treatment~23. Prior participation in any Onyx-sponsored Phase 3 trial~24. Patients with contraindication to dexamethasone~25. Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment~26. Ongoing graft-versus-host disease~27. Patients with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to enrollment~28. Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment~29. Any other clinically significant medical disease or psychiatric condition that, in the Investigator's opinion, may interfere with protocol adherence or a patient's ability to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Carfilzomib (Type: EXPERIMENTAL): In phase 1 participants were assigned to one of four sequential dose-escalating cohorts to receive 45, 56, 70 or 88 mg/m² carfilzomib administered by intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle. Participants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15.~In phase 2 participants received carfilzomib at the maximum tolerated dose (MTD) established in the Phase 1 portion of the study on days 1, 8 and 15 plus 40 mg dexamethasone IV or orally at the same schedule as used in the Phase 1 portion of the study.~Participants were treated until confirmed progressive disease, unacceptable toxicity, withdrew consent for further treatment, were lost to follow-up, died, or the sponsor closed the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).